Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

The research and investment firm believes Nvidia ( NASDAQ: NVDA) will slice into AMD's market share in these two areas.

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

Major stock indexes closed lower on Friday, after the week saw a flurry of events, including DeepSeek scare and earnings ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

The stock has dropped 56% over the last 12 months. Analysts led by Salveen Richter lowered Moderna's rating to neutral from buy as they say Moderna has limited visibility on the revenue stream for ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Apellis Pharmaceuticals (APLS – Research Report) received a Hold rating and price target from Goldman Sachs analyst Salveen Richter today. The company’s shares closed yesterday at $33.66.

RBC Capital maintains a Neutral rating on Vertex. Goldman Sachs analyst Salveen Richter writes suzetrigine could become the first non-opioid treatment for acute pain approved in over 20 years.